Kairos Pharma enters consulting pact with Cross Current for $700K total compensation

Kairos Pharma, LTD.

Consulting agreement for $200,000 cash and restricted shares valued at $500,000, subject to a six-month true-up to maintain $500K value.
Shares cannot exceed 9.99% of outstanding common stock; vest after six months with possible additional 'true up' shares.
Services include investor marketing, M&A canvassing, capital markets advisory; term is 24 months starting from NYSE American listing.
Compensation and agreement effective upon listing (Start Date); registration statement on Form S-8 planned within 30 days after listing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.